4. Patient Case 1 Peggy

5. Peggy Interactive Case Question

6. Clinical Considerations/Questions for Peggy

7. Adding Prandial Insulin in T2D

8. Patient Case 2 Jonathan

9. Jonathan Interactive Case Question

10. Clinical Considerations/Questions for Jonathan

11. LADA When T1D Masquerades as T2D

12. Adding Insulin in LADA

13. Case 3 Steven

14. Steven Interactive Case Question

15. Clinical Considerations for Steven

16. Case 4 Maria

17. Maria’s Blood Glucose Log

18. Identifying Hypoglycemic Events

19. Clinical Observations for Maria

20. Individualizing Prandial Insulin

21. Practical Discussions for Use of Prandial Insulin FAQs

22. Case 5 Michelle

23. Case 6 Jason

25. Rationale for and Limitations of Prandial Insulin Therapy in T2D

26. The Effect of Postmeal Hyperglycemia

27. Current and Emerging Prandial Insulins United States, September 2017

28. Timing of Prandial Insulin Injections

29. Inhaled Insulin (Technosphere®) in T2D

30. Efficacy and Safety of Inhaled Prandial Insulin Meta-Analysis

31. U-200 Lispro (in T1D)

32. Time-to-Peak Action Correlates With HbA1c

33. Current Insulin Treatment Challenges

35. Designing an Ultrafast-Acting Insulin

36. Changing the Formulation

37. Faster Aspart vs Insulin Aspart via SC Injection

38. Onset® 1 Trial Design

39. Onset® 1 Mean HbA1c Over Time

40. Onset® 1 Estimated Mean HbA1c Change From Baseline

41. Onset® 1 PPG Increment at Week 26

42. Onset® 2 Trial Design

43. Onset® 2 Mean HbA1c Over Time

44. Onset® 2 PPG Increment at Week 26

45. Comparing Faster Aspart and Insulin Aspart in CSII

46. PPG in CSII with Faster Aspart

47. BioChaperone Lispro

48. Ultra-Rapid Insulin Lispro

49. Summary

51. What Do the Data Mean, and How Will New Prandial Insulin Products Affect Practice?